Different strokes for AGY

AGY Therapeutics Inc.'s deal with M's Science Corp. gets AGY into the clinic, but in an indication where many others have broken their picks: stroke.

AGY is taking a different tack, and plans to develop its newly acquired AGY-94806 sigma receptor agonist to improve functional recovery in stroke patients rather than treating the stroke while it's occurring. But while the company is side-stepping the relatively small window for treating stroke, improving functional recovery is essentially uncharted waters - there are no FDA approved drugs for the indication and AGY essentially must blaze a trail through the clinic...